Metoclopramide in Adults
Metoclopramide is conditionally recommended for gastroparesis at 5-10 mg orally before meals (or 15 mg intranasally), with treatment efficacy assessed at 4-8 weeks and drug holidays of 1-4 weeks every 8-12 weeks to minimize tardive dyskinesia risk, which carries an FDA black box warning. 1
Primary Indication
- Gastroparesis (diabetic or idiopathic): Relief of nausea, vomiting, and early satiety symptoms 1
- Prevention of chemotherapy-induced nausea/vomiting (high-dose IV: 1-2 mg/kg) 2
- Prevention of postoperative nausea/vomiting (10 mg IM/IV) 2
- Facilitation of small bowel intubation and radiological examinations 2
Dosing Schedule
For Gastroparesis:
- Oral (tablet/liquid): Start 5 mg three times daily before meals, may increase to 10 mg before meals 1
- Intranasal: 15 mg before meals and at bedtime 1
- IV/IM (severe symptoms): 10 mg slowly over 1-2 minutes 2
For Chemotherapy-Induced Nausea:
- High emetogenic drugs (cisplatin/dacarbazine): 2 mg/kg IV over ≥15 minutes, 30 minutes before chemotherapy, repeat every 2 hours × 2 doses, then every 3 hours × 3 doses 2
- Less emetogenic regimens: 1 mg/kg per dose may suffice 2
Renal Impairment:
- CrCl <40 mL/min: Initiate at approximately half the recommended dose 2
Duration Limits
Critical limitation: The 2025 AGA guidelines recommend drug holidays of 1-4 weeks every 8-12 weeks to improve tolerability and reduce tardive dyskinesia risk 1. Despite FDA recommendations limiting use to 12 weeks maximum, real-world data shows approximately 15-20% of patients receive prescriptions beyond 90 days 3. Efficacy and adverse effects should be assessed at 4-8 weeks to determine continuation 1.
The actual risk of tardive dyskinesia is approximately 0.1% per 1000 patient-years—far lower than the previously estimated 1-10% cited in older guidelines 4. However, the FDA black box warning remains in effect 1.
Contraindications (from FDA Label)
- Mechanical gastrointestinal obstruction
- Pheochromocytoma (may precipitate hypertensive crisis)
- History of seizure disorder
- Known hypersensitivity to metoclopramide
- Concurrent use with drugs likely to cause extrapyramidal reactions
- Possible atrioventricular block risk 2
High-Risk Populations Requiring Precautions
Patients at increased risk for adverse events 1:
- Elderly patients (especially females)
- Patients on psychotropic agents (higher discontinuation risk)
- Diabetic patients
- Renal failure (dose reduction required)
- Hepatic failure
These groups have lower thresholds for neurological complications 4.
Key Adverse Effects to Monitor
Extrapyramidal Symptoms (EPS):
- Acute dystonic reactions: 0.2% (1 in 500) at standard doses; 2% in adults >30-35 years at high doses (1-2 mg/kg); 25% or higher in patients <30 years without prophylactic diphenhydramine 2
- Symptoms: involuntary limb movements, facial grimacing, torticollis, oculogyric crisis, tongue protrusion, trismus, opisthotonus 2
- Treatment: 50 mg diphenhydramine IM reverses symptoms 2
Other Neurological Effects:
- Tardive dyskinesia (black box warning): involuntary movements of tongue, face, mouth, jaw, trunk, extremities 2
- Parkinsonian symptoms: bradykinesia, tremor, rigidity, mask-like facies 2
- Akathisia: anxiety, agitation, inability to sit still, pacing 2
- Neuroleptic malignant syndrome (rare): hyperthermia, rigidity, altered consciousness, autonomic instability 2
Common Effects:
- Restlessness, drowsiness (70% at high doses), fatigue, lassitude 2
- Endocrine: galactorrhea, amenorrhea, gynecomastia, impotence (hyperprolactinemia) 2
Clinical Implementation Algorithm
- Before initiating: Discuss FDA black box warning for tardive dyskinesia with patient 1
- Start low: 5 mg PO three times daily before meals 1
- Titrate gradually based on symptom response and tolerability
- Assess at 4-8 weeks: Evaluate efficacy and monitor for movement disorders 1
- Implement drug holidays: 1-4 weeks off every 8-12 weeks 1
- Continue monitoring: Assess for adverse effects throughout treatment duration 1
Important Caveats
- Dietary interventions first: The AGA experts recommend small-particle, low-fat, low-residue diets before or concurrent with pharmacologic therapy 1
- Antiemetics as needed: Consider 5-HT3 antagonists (ondansetron), H1 antagonists (promethazine), or D2 antagonists (prochlorperazine) for breakthrough nausea without affecting gastric emptying 1
- Alternative if intolerant: Domperidone may be considered for patients with neurologic adverse effects from metoclopramide, though not recommended as first-line 1
- Drug interactions: Metoclopramide may interact with psychotropic medications, increasing adverse event risk 1